MASLD Management in Spain: A Nationwide Survey of Gastroenterologists Highlighting Gaps in Risk Assessment and Primary Care Coordination
Journal of Clinical Medicine · 24.04.2026 · 15 (9) · 3259
DOI: 10.3390/jcm15093259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.04.2026. Verfasst von Carolina Jiménez-González und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Research in Digestive Diseases, Gastroenterology and Hepatology Department, Valdecilla Research Institute (IDIVAL), Marqué…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Horizon's research and innovation program, Instituto de Salud Carlos III, European Union-NextGenerationEU.
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and a major contributor to the global cardiometabolic burden. Early identification of patients at risk of metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis is essential to prevent liver-related and cardiovascular complications. In Spain, the burden of MASLD is increasing, yet information on routine clinical management by gastroenterologists remains limited.
Methods
A nationwide cross-sectional online survey was conducted among members of the Spanish Society of Digestive Diseases (SEPD). The questionnaire explored five domains: MASLD knowledge, use of non-invasive biomarkers and imaging, awareness and implementation of clinical guidelines, cardiometabolic and alcohol-related risk assessment, and coordination with primary care.
Results
A total of 429 specialists responded, 33.1% reported more than 20 years of practice and most worked in public hospitals, including 29.2% in large tertiary centers. Awareness of the MASLD definition was high, and 91.2% identified fibrosis as the main prognostic determinant. Non-invasive fibrosis biomarkers were widely used, whereas steatosis biomarkers were less frequently applied. Elastography was available to 96.1%. Guideline knowledge was reported by 80.4%, although implementation was lower. Cardiovascular risk evaluation varied: 75.1% reported systematic screening. Alcohol consumption was usually assessed. Coordination with primary care was limited: 91.1% expressed concerns regarding physicians’ familiarity with MASLD classification, and only 31.1% reported shared protocols.
Conclusions
Spanish gastroenterologists show high awareness of MASLD and broad access to non-invasive diagnostic tools. However, important gaps remain in cardiovascular and alcohol risk assessment, guideline implementation, and coordination with primary care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical and Translational Research in Digestive Diseases, Gastroenterology and Hepatology Department, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
- Family and Community Medicine, Vargas Health Centre, Primary Care Department of the Cantabrian Health Service, 39011 Santander, Spain.
- Family and Community Medicine, Bezana Health Center, Department of Medicine and Psychiatry, University of Cantabria IDIVAL, Santa Cruz de Bezana, 39100 Cantabria, Spain.
- Cantabria Cohort, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
- School of Medicine, University of Cantabria, 39011 Santander, Spain.
- Medicine AI, 28028 Madrid, Spain.
ORCID-Profile: Carolina Jiménez-González, Paula Argos Vélez, Ana Belén García-Garrido, Antonio Cuadrado, Paula Iruzubieta, Javier Crespo
Förderung
- European Horizon's research and innovation program
- Instituto de Salud Carlos III
- European Union-NextGenerationEU
- European Horizon’s research and innovation program
Zitieren
APA
Jiménez-González, C., Argos Vélez, P., Cayón, L., García-Garrido, A. B., Fontanillas Garmilla, N., Cuadrado, A., Iruzubieta, P., & Crespo, J. (2026). MASLD Management in Spain: A Nationwide Survey of Gastroenterologists Highlighting Gaps in Risk Assessment and Primary Care Coordination. Journal of Clinical Medicine, 15(9), 3259. https://doi.org/10.3390/jcm15093259
Vancouver
Jiménez-González C, Argos Vélez P, Cayón L, García-Garrido AB, Fontanillas Garmilla N, Cuadrado A, et al. MASLD Management in Spain: A Nationwide Survey of Gastroenterologists Highlighting Gaps in Risk Assessment and Primary Care Coordination. Journal of Clinical Medicine. 2026;15(9):3259. doi:10.3390/jcm15093259
BibTeX
@article{JimnezGonzlez2026,
author = {Jiménez-González, Carolina and Argos Vélez, Paula and Cayón, Lorena and García-Garrido, Ana Belén and Fontanillas Garmilla, Noelia and Cuadrado, Antonio and Iruzubieta, Paula and Crespo, Javier},
title = {MASLD Management in Spain: A Nationwide Survey of Gastroenterologists Highlighting Gaps in Risk Assessment and Primary Care Coordination},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {9},
pages = {3259},
doi = {10.3390/jcm15093259}
}
EUVIMED